Pathology Technology Australia appoints new Board members to drive next phase of strategic plan

Pathology Technology Australia (PTA) has expanded its Board with the appointment of three senior leaders, joining Allison Rossiter, CEO of Genetic Signatures, who serves as Chair.

Helen Speirs, Associate Director and Leader of Large National Initiatives at Illumina across APAC, the Middle East, and Africa, brings expertise in advancing the uptake of genomic technologies for precision healthcare. She oversees strategic partnerships and leads a team driving initiatives such as Phase II of Singapore’s PRCISE program. Previously, she served as Deputy Director at the Ramaciotti Centre for Genomics at the University of NSW.

“My professional ethos is rooted in quality and excellence in service provision and delivery of programs, and in the integration of business strategy and operations management to drive projects that shape the future of healthcare,” commented Speirs.

Kensi Naicker, General Manager of Hologic ANZ, brings breadth and versatility from a career spanning R&D labs, startups, and global multinationals.

“I have a strong patient and customer focus coupled with a clear strategic lens to ensure advocacy for cutting edge industry led solutions,” he said.

Sandrine Richard, Business Unit Director Asia Pacific at Diagnostica Stago, is a strategist who thrives at the intersection of operations, transformation, and innovation. She is driven by improving patient outcomes, elevating stakeholder engagement, and building sustainable growth in a health system under pressure.
“I value integrity, collaboration, and purpose-driven leadership. My vision is to help shape a future where pathology technology is seamlessly embedded in patient care, policy, and public health strategy,” she stated.

Dean Whiting, CEO of PTA, welcomed the appointments, saying: “Bringing a wealth of strategic leadership and management experience across a broad range of technologies, we are thrilled to be drawing on their unique expertise as we build towards a refreshed strategic plan for 2026 and beyond.”

They join a seasoned lineup of existing Board members, including Novak Laforest, Enterprise Solutions Director at Abbott Core Diagnostics ANZ and Co-Vice Chair of the PTA Board; Fabian Ehlen, Head of Finance and Operations at Roche Diagnostics; Simon Giuliano, Head of Sales at Oxford Nanopore Technologies; and Jeremy Tyson, Commercial Manager Pacific at Bio-Rad and Co-Vice Chair of the PTA Board.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.